We believe that understanding the interactions between HO-1 and SIRT1 in NAFLD and related hepatic fibrosis will lead to the development of new biomarkers and therapeutic strategies to fight hepatic dysfunction. The gene discussed is HMOX1; the disease is metabolic dysfunction-associated steatotic liver disease.